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Resum
Avui en dia, el descobriment de medicaments es basa majoritàriament en tècniques de simulació
per ordinador. Els processos pel descobriment/disseny de medicaments a través del disseny as-
sistit per ordinador ha jugat un paper fonamental en el desenvolupament de petites mol·lècules
terapèutiques durant les últimes tres dècades. A causa del creixement exponencial de la quantitat
de dades mol·leculars i del ràpid avenç de les tecnologies, les oportunitats per al descobriment
de medicaments ha crescut considerablement. El mode d’acció d’un medicament sobre el seu
objectiu pot ser normalment classificat como a positiu (activador, potenciador, agonista, etc.) o
negatiu (inhibidor, bloquejador, antagonista, etc.). L’objectiu d’aquesta tesis és contribuïr en el
camp de la “network pharmacology” a través de la creació d’una xarxa medicament-objectiu i
la investigació de les seves propietats. Les arestes amb signe d’una xarxa medicament-objectiu
poden ser útils per explorar d’una manera sistemàtica els mecanismes d’acció combinats de múl-
tiples medicaments en el conjunt d’objectius comuns. En aquesta tesi es mostra que per a una
xarxa medicament-objectiu humana la majoria de parells de medicaments tendeixen a tenir efec-
tes sinèrgics en els objectius comuns, és a dir, els parells de medicaments tendeixen a tenir modes
d’acció amb el mateix signe en la majoria dels objectius compartits, especialment pels objectius
principals farmacològics d’un medicament. Es proposen alguns mètodes per calcular aquesta si-
nergia, així com per estimar la influencia dels medicaments en els efectes secundaris d’un altre
medicament.
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Resumen
Hoy en día, el descubrimiento de fármacos se basa mayoritariamente en técnicas de simulación
por ordenador. Los procesos para el descubrimiento/diseño de fármacos a través del diseño asis-
tido por ordenador ha jugado un papel fundamental en el desarrollo de pequeñas moléculas
terapéuticas durante las últimas tres décadas. A causa del crecimiento exponencial de la cantidad
de datos moleculares y del rápido avance de las tecnologías, las oportunidades para el descu-
brimiento de fármacos han crecido considerablemente. El modo de acción de un fármaco sobre
su objetivo puede ser normalmente clasificado como positivo (activador, potenciador, agonista,
etc.) o negativo (inhibidor, bloqueador, antagonista, etc.). El objetivo de esta tesis es contribuir
en el campo de la “network pharmacology” a través de la creación de una red fármaco-objetivo
y la investigación de sus propiedades. Las aristas con signo de una red fármaco-objetivo pueden
ser útiles para explorar de un modo sistemático los mecanismos de acción combinados de múl-
tiples fármacos en el conjunto de objetivos comunes. En esta tesis se muestra que para una red
fármaco-objetivo humana la mayoría de pares de fármacos tienden a tener efectos sinérgicos en
los objetivos comunes, es decir, los pares de fármacos tienden a tener modos de acción con el mis-
mo signo en la mayoría de los objetivos compartidos, especialmente para los objetivos principales
farmacológicos de un fármaco. Se proponen algunos métodos para calcular esta sinergia, así como
para estimar la influencia de los fármacos en los efectos secundarios de otro fármaco.
iii

Abstract
Nowadays, drug discovery frequently relies on computer modeling techniques. Computer-aided
drug discovery/design methods have played a major role in the development of therapeutically
important small molecules for over three decades. Due to the exponential growth of molecular
data and fast advancement in technologies, the efforts of drug discovery have been tremendously
amplified. The mode of action of a drug on its targets can often be classified as being positive (ac-
tivator, potentiator, agonist, etc.) or negative (inhibitor, blocker, antagonist, etc.). The aim of this
thesis is to contribute to the field of "network pharmacology" by introducing the idea of signed
drug-target network and investigating its properties. The signed edges of a drug-target network
can be used to explore in a systematic way the combined mechanisms of action of multiple drugs
on the ensemble of common targets. In this thesis it is shown that for the signed human drug-
target network the majority of drug pairs tend to have synergistic effects on the common targets,
i.e., drug pairs tend to have modes of action with the same sign on most of the shared targets,
especially for the principal pharmacological targets of a drug. Methods are proposed to compute
this synergism, as well as to estimate the influence of the drugs on the side effect of another drug.
v
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Introduction
For patients, new medicines can offer fewer side effects, fewer hospitalizations, improved quality
of life, increased efficiency, and importantly, extended lives. But developing medicines is a long,
complex process. From initial drug discovery to a marketable medicine is a long, challenging
road. It takes about 12 - 15 years from discovery to the approved medication and requires an
investment of about US $2.6 billion. On average, from more than a million screened molecules
only one is investigated in late stage clinical trials and is finally made available for patients.
Drug discovery is the process through which potential new medicines are identified. It involves a
wide range of scientific disciplines, including biology, chemistry and pharmacology. Historically,
drugs were discovered through identifying the active ingredient1 from traditional remedies or
by serendipitous discovery. In the past, substances were screened for biological activity without
knowledge of the biological target2. Only after an active substance was identified was an effort
made to identify the target. This approach is known as classical pharmacology, forward pharma-
cology, or phenotypic drug discovery.
Nowadays, drug discovery frequently but not necessarily relies on computer modeling techniques.
Computer-aided drug discovery/design methods have played a major role in the development of
therapeutically important small molecules for over three decades. Due to the exponential growth
of molecular data and fast advancement in technologies, the efforts of drug discovery have been
tremendously amplified. The philosophy of drug design has been transformed from “one drug
1The one that has biological activity or pharmacological activity, in other words, describes the beneficial or adverse
effects of a drug on living matter.
2A biological target is anything within a living organism to which some other entity (like an endogenous ligand
or a drug) is directed and/or binds, resulting in a change in its behavior or function. Examples of common classes of
biological targets are proteins and nucleic acids.
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one target” to “one drug multiple targets”, coined as polypharmacology. Polypharmacology is
emerging as the next paradigm of drug discovery because of its value in treating complex diseases
([5], [9], [14]). The Polypharmacological approaches aim to discover the unknown off-targets for
the existing drugs (also known as drug repurposing). The approach needs the systematic integra-
tion of the data derived from different disciplines including computational modeling, synthetic
chemistry, in vitro/in vivo pharmacological testing, and clinical studies. Network pharmacology
([2], [3], [11], [17], [18]) is also a good "system" way to understand the effects (and side effects) of
drugs on an organism. A network viewpoint can help in understanding the effect of a drug on sys-
tem properties such as robustness, resilience and redundancy, and can be used for system-driven
drug discovery [15].
Although not designed on purpose, numerous drugs are known for their multi-targeting activ-
ities. One such example is Aspirin, often used as an analgesic to relieve minor pains or as an
antipyretic to reduce fever; also acts as an anti-inflammatory medication to treat rheumatoid
arthritis, pericarditis, and Kawasaki diseases. Additionally, it has been used in the prevention
of transient ischemic attacks, strokes, heart attacks, pregnancy loss, and even cancer. Similarly,
many targets are known to be bound by different drugs. Combining together all known drugs
and all known targets, we obtain a drug-target network.
Network representations of drug-target interactions have already been used for several tasks, like
to extrapolate information of functional nature on the action of the drugs, to predict novel puta-
tive drug-target interactions, and to provide strategies for an efficient use of multi-drug therapies,
see [12] for an overview.
Systematic attempts to identify new drug-target interactions are very frequent in the literature,
based on sequence [1], structure [16], but also on chemical and phenotypical similarity among
drugs and sets of ligands ([10], [19]), often leading to a large number of low-affinity interactions.
When investigating a given drug-target network (for instance reconstructed from a database such
as DrugBank [20], which is also our database of choice), most computational methods rely prin-
cipally on the topological information that can be obtained from the bipartite drug-target graph
and on the ontology of its constituent components. In this work we aim to add another element
of functional nature in the network-based investigation of drug-target interactions, namely the
3information on the mode of action of the interactions, i.e. the mechanisms of action of a drug on
its targets.
A DTI3 bipartite network is constructed with known DTI data extracted from DrugBank. It is
a bipartite graph having two classes of nodes: drugs and targets. The edges represent known
actions of a drug on a target, in our case, classified as positive or negative. Selecting only human
targets among all the possible organisms, a subnetwork can be extracted. It is on this subnetwork
that the thesis is focused. On our drug-target network, characterizing the modes of action as
positive or negative corresponds to associating a sign to the edges of the bipartite graph. Signed
graphs have been frequently used in Systems Biology ([7], [8], [13], [4]), and we can draw inspi-
ration from this literature to formulate and solve problems which are meaningful and insightful
also for our signed drug-target network.
This thesis has been conducted in the Automatic Control Department of the University of Linköping,
Sweden and supervised by Claudio Altafini.
3Drug-target interactions.

2
Background, Materials and Methods
2.1 Biological Overview
In this section we give a basic overview on the biological aspects of the thesis. Drugs and targets
will be very present throughout the thesis, therefore some definitions need to be made. A drug is
a chemical substance that has known biological effects on humans or other animals. It is used in
the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or
mental well-being.
A target is a protein, macromolecule, nucleic acid, or small molecule to which a given drug binds,
resulting in an alteration of the normal function of the bound molecule and a desirable therapeu-
tic effect. Drug targets are most commonly proteins such as enzymes, ion channels, and receptors.
Although organisms like E.Coli and Yeast appear in this project, the main studied organism is
Human. The action of drugs on the human body is called pharmacodynamics. The drugs that
enter the human tend to stimulate certain receptors, ion channels, act on enzymes or transporter
proteins (targets). As a result, they cause the human body to react in a specific way.
There are two ways in which a drug can interact with its targets:
• Agonists - they stimulate and activate the target.
• Antagonists - they stop the agonists from stimulating the target.
On its side, targets can be classified as:
• Main target - for which the drug has been designed.
5
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• Off-target - non-main targets, i.e., side effects of the drug.
A target can act as both main target and off-target, depending on the drug with which is inter-
acting. This is also related with the ’pharmacological action’ concept. If a certain drug-target
interaction has pharmacological action it means that this specific drug has been designed to act
on this specific target, in other words, the target in this interaction will be a main target.
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2.2 DrugBank Database
The DrugBank database is a unique bioinformatics and cheminformatics resource that combines
detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug
target (i.e. sequence, structure, and pathway) information.
The database used in this thesis contains 7795 drug entries including 1634 FDA-approved1 small
molecule drugs, 169 FDA-approved biotech (protein/peptide) drugs, 89 nutraceuticals2 and over
6000 experimental drugs. Additionally, 4313 non-redundant protein (i.e. drug target/enzyme/transporter/carrier)
sequences are linked to these drug entries. Each DrugCard entry contains more than 200 data
fields with half of the information being devoted to drug/chemical data and the other half de-
voted to drug target or protein data. Among this vast information offered by DrugBank database
only small part of it will be used. For the purpose of this project, the interesting data fields are:
• Drug information: Standard name of drug as provided by drug manufacturer and Accession
Number.3
• Target information: Name of the protein or macromolecule (or other small molecule) and
UniProt ID/Name.
• Interaction information between them: Action, Affected organism and Pharmacological ac-
tion (yes, no or unknown).
When browsing DrugBank, many are the possible mechanisms of action of a drug on its targets.
Although qualitatively different and applicable to different categories of targets (proteins, macro-
molecules, nucleic acids, small molecules, etc.), these modes of action can be reasonably classi-
fied as positive (agonists) or negative (antagonists). If some modes of action admit such a signed
classification, several others, such as “modulators” or “binder” are instead impossible to classify
with a sign, and hence cannot be included in the analysis we are proposing in this thesis. Hav-
ing extracted the interesting data fields from the database, we can construct a table with all this
information. This table has 16386 drug-target connections with its associated action and other
relevant information. A small part of it is shown in Table 2.2. This table can be converted into a
1FDA is a federal agency of the United States Department of Health and Human Services, one of the United States
federal executive departments. The FDA is responsible for protecting and promoting public health through the
regulation and supervision of prescription and over-the-counter pharmaceutical drugs (medications) among other
things.
2Drug is a food product which has experimentally confirmed health benefits.
3Unique DrugBank accession number consisting of a 2 letter prefix (DB) and a 5 number suffix.
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Actions
Positive (Agonists) agonist; partial agonist; activator; stimulator; inducer; positive al-
losteric modulator; potentiator; positive modulator
Negative (Antagonists) inhibitor; inhibitory allosteric modulator; inhibitor, competitive; an-
tagonist; partial antagonist; negative modulator; inverse agonist;
blocker; suppressor; desensitize the target; neutralizer; reducer
Not classifiable unknown; other; other/unknown; binder; antibody; cofactor; chap-
erone; modulator; metabolizer; multitarget; incorporation into and
destabilization; cleavage; ligand; product of; component of; cross-
linking/alkylation; intercalation; binding; adduct; chelator; al-
losteric modulator; acetylation
Table 2.1: Complete list of categories.
Drug ID Target ID Action/s Organism Pharmacological
action
’DB00001’ ’BE0000048’ ’inhibitor’ ’Human’ ’yes’
’DB00006’ ’BE0000048’ ’inhibitor’ ’Human’ ’yes’
’DB00009’ ’BE0000211’ ’activator’ ’Human’ ’yes’
’DB00009’ ’BE0000240’ [] ’Human’ ’unknown’
’DB00055’ ’BE0000048’ [] ’Human’ ’unknown’
’DB00055’ ’BE0000240’ [] ’Human’ ’unknown’
’DB00055’ ’BE0000016’ ’multitarget’ ’Human’ ’yes’
’DB00086’ ’BE0000211’ ’activator’ ’Human’ ’yes’
’DB03147’ ’BE0001961’ [] ’Escherichia coli’ ’unknown’
...
...
...
...
...
Table 2.2: Sample of the complete list. [] means not known action between this drug and tar-
get. If the non-classifiable actions according to Table 2.1 are discarded, the list is significantly
reduced.
Total Only classifiable actions
’Drugs’ ’7795’ ’1513’
’Targets’ ’4313’ ’997’
’drug-target connections’ ’16386’ ’4624’
Table 2.3: The table is considerably reduced(about 72%) when only considering the classifi-
able actions.
graphic network, then the drugs and targets are visually represented as circles and its interaction
with a line between them. Being not the main focus of this thesis to study many different types of
organisms, three among the 521 that DrugBank offers will be analysed. The one with more data
available is Human, so this will be the most extensively analysed. Although there is less available
data, Escherichia coli and Yeast are also present. Some information about this three organisms:
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Figure 2.1: Graphical representation of the previous table.
Human
Modern humans (Homo sapiens) are the only remaining members of Hominina clade, a branch of
the taxonomical tribe Hominini belonging to the family of great apes. Like all mammals, humans
are a diploid4 eukaryotic5 species.
Human
’Kingdom’ ’Animalia’
’Phylum’ ’Chordata’
’Clade’ ’Synapsida’
’Class’ ’Mammalia’
’Order’ ’ Primates’
’Suborder’ ’Haplorhini’
’Family’ ’Hominidae’
’Genus’ ’Homo’
’Species’ ’Homo sapiens’
Table 2.4: Taxonomy of Human.
Escherichia coli
Also known as E. coli, it is maybe the most studied prokaryote6 organism. It is a bacterium that
is commonly found in the lower intestine of endotherms7. Although the majority of the strains8
are innocuous, some of them can cause a severe foodborne diseases. To show an example of this
4Cell that has two homologous copies of each chromosome (46 total chromosomes in the human case). Nearly all
mammals are diploid organisms.
5Organism whose cells contain a defined nucleus and other organelles enclosed within membranes.
6A prokaryote is a single-celled organism that lacks a membrane-bound nucleus.
7Warm-blooded organisms
8A strain is a genetic variant or subtype of a micro-organism.
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Escherichia coli
’Domain’ ’Bacteria’
’Phylum’ ’Proteobacteria’
’Class’ ’Gammaproteobacteria’
’Family’ ’Enterobacteriaceae’
’Genus’ ’Escherichia’
’Species’ ’E. coli’
Table 2.5: Taxonomy of Escherichia coli.
severity we can refer to the outbreak of foodborne illness focused in northen Germany in May
through June 2011 which was caused by a novel strain of Escherichia coli O104:H4. 53 of the
3,950 affected people died.
The E. Coli strains that can be found in DrugBank are: Escherichia coli(strain K12) and Es-
cherichia coli O1:K1.
Yeast
Yeasts are eukaryotic microorganisms classified as members of the fungus kingdom. Yeasts are
unicellular, although some species can also develop multicellular characteristics. Some of them
are opportunistic pathogens that can cause infection in people with compromised immune sys-
tems. These are the ones that appear in DrugBank, in particular, some species of the Candida
genus. Candida is a genus of yeasts that is the most common cause of fungal infections. Many
Candida
’Kingdom’ ’Fungi’
’Division’ ’Ascomycota’
’Class’ ’Saccharomycetes’
’Order’ ’Saccharomycetales’
’Family’ ’Saccharomycetaceae’
’Genus’ ’Candida’
’Species’ ’Candida albicans’
Table 2.6: Taxonomy of Yeast.
species are harmless commensals9 or endosymbiontsany10 of hosts including humans; however,
when mucosal barriers are disrupted or the immune system is compromised they can invade and
cause disease. The Candida strains that can be found in DrugBank are: Candida albicans (strain
SC5314 / ATCC MYA-2876), Candida rugosa and Candida glabrata (strain ATCC 2001 / CBS 138
/ JCM 3761 / NBRC 0622 / NRRL Y-65).
9Class of relationships between two organisms where one organism benefits from the other without affecting it.
10Organism that lives within the body or cells of another organism.
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2.3 Graph Theory
The word graph was first introduced by James Joseph Sylvester, an English mathematician, in
1878. Euler laid the foundations of graph theory in 1736 sixty years before, solving the Seven
Bridges of Kønigsberg problem. This problem is perhaps the best-known example in graph the-
ory. It was an unresolved problem until solved by Leonhard Euler in 1736, by means of a graph.
In the last decades graph theory has become very popular thanks to the many applications in
Figure 2.2: Two islands, C and D, formed by the Pregel River in Königsberg (then the capital
of East Prussia but now renamed Kaliningrad and in West Soviet Russia) were connected
to each other and to the banks A and B with seven bridges, as shown in this Figure. The
problem was to start at any of the four land areas of the city, A, B, C and D, walk over each
of the seven bridges exactly once, and return to the starting point. Euler represented this
situation by means of a graph. The vertices represent the land areas and the edges represent
the bridges. Euler proved that a solution for this problem does not exist.
all scientific field starting from mathematics, engineering, physics, chemistry, informatics and
bioinformatics, neuroscience, social sciences, economy and in numerous other areas. The neces-
sity to store, manage and analyse these data had driven a large community of scientist to focus
their studies on complex networks theory and, as a consequence, in graph theory. Because of its
inherent simplicity, graph theory has a very wide range of applications. A graph can be used to
represent almost any physical situation involving discrete objects and a relationship among them.
In this chapter we will shortly present some useful definitions and notations about graph theory.
The ’graphical representation’ of the table seen in Fig.2.1 is an example of ’network’ or ’graph’
that will be used in this thesis. A graph consists of a finite set of vertices, a finite set of edges,
and a rule which tells us which edges join which pairs of vertices. Mathematically, a graph is a
pair G = (N, E) comprising a set N of vertices together with a set E of edges, formed by pairs of
vertices. In our graph, the nodes are the drugs and targets, and the edges are the connections be-
tween them. The most common representation of a graph is by means of a diagram, in which the
vertices are represented as points and each edge as a line segment joining its end vertices. We have
12 2 Background, Materials and Methods
Figure 2.3: General graph.
N = n1, ..., n5
for the nodes and
E = (n1, n2), (n2, n3), (n2, n4), (n3, n5)
for the edges. Similarly, the edges can also be labeled with letters or numbers. The graph can be
directed or undirected, that means the edges can be ordered or not ordered. From now on, only
Figure 2.4: Left panel: Undirected graph. Right panel: Directed graph.
undirected and simple graphs will appear. So
E = e1, ..., e4
n = |V| and m = |E| can be used to denote the number of vertices and edges respectively. When a
vertex ni is an end vertex of some edge ej , ni and ej are said to be incident with each other. In Fig.
2.4, for example, edges e1, e3, and e2 are incident with vertex n2. Two edges are said to be adjacent
if they are incident on a common vertex. For example, e1 and e3 in Fig. 2.4 are adjacent. Similarly,
two vertices are said to be adjacent if they are the end vertices of the same edge. In Fig. 2.4, n1
and n2 are adjacent.
The number of edges incident on a vertex ni is called the degree, d(ni), of a vertex ni . In Fig.
2.4, for example, d(n2) = 3, d(n3) = 2 and d(n1) = d(n4) = d(n5) = 1. The degree of a vertex is
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sometimes also referred to as its valency.
Intuitively, the concept of connectedness is obvious. A graph is connected if we can reach any
vertex from any other vertex by travelling along the edges. In other words, a graph is said to be
connected if there is at least one path between every pair of vertices in G. Otherwise, G is discon-
nected.
It is easy to see that a disconnected graph consists of two or more connected graphs. Each of
these connected subgraphs is called component. A signed graph is a graph in which each edge has
a positive or negative sign. A bipartite graph is a graph whose vertices can be divided into two
disjoint sets U and V (that is, U and V are each independent sets) such that every edge connects a
vertex in U to one in V.
Then, the studied graphs in this thesis are signed and bipartite graphs.
2.3.1 Null model
A null model is a model generated with random samples of a specific distribution where certain
elements are constant and some others are allowed to vary stochastically. Null model helps in
specifying a statistical distribution or randomization of the observed data, designed to predict the
outcome of a random process without specifying all of its parameters. Applied to graph theory,
a null model is a graph which matches one specific graph in some of its structural features, but
which is otherwise taken to be generated as an instance of a random graph. Null model graph
is used to match some randomly generated graph, and is believed to be similar until it is proven
otherwise.
The null model is used as a term of comparison, to verify whether the graph in question displays
some feature, such as community structure, or not. There are several null models that can be
used. One null model is that proposed by Newman and Girvan and consists of a randomized
version of the original graph, where edges are rewired at random, under the constraint that the
expected degree of each vertex matches the degree of the vertex in the original graph.
Cycles
A cycle consists of a sequence of vertices starting and ending at the same vertex, with each two
consecutive vertices in the sequence adjacent to each other in the graph. No repetitions of vertices
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and edges are allowed, other than the repetition of the starting and ending vertex.
The cycle with n vertices is called Cn. The number of vertices in Cn equals the number of edges,
and every vertex has degree 2; that is, every vertex has exactly two edges incident with it. A cycle
with an even number of vertices is called an even cycle; a cycle with an odd number of vertices
is called an odd cycle. A bipartite graph, as our studied graph, does not contain any odd-length
cycles.
The sign of a cycle is the product of the signs of its edges. For convenience we denote the sign
of an edge by +1 or -1 when it is positive or negative. A cycle is positive if it contains an even
number of negative edges, and it is negative otherwise. Thus, in particular, a cycle containing
only positive edges is positive, since the number of negative edges is zero, an even number. By
definition, a signed graph is balanced if and only if each of its cycles is positive.
4-edged cycles will be studied in this thesis, that is, a cycle graph with 4 vertices.
2.4 Statistical hypothesis testing
A statistical hypothesis test is a method of statistical inference to judge if a certain property that
is supposed true for a statistical population is compatible with what observed in a sample of this
population.
By means of this theory the statistical problem is approached by considering a certain hypothesis
H0 and an alternative hypothesis H1. After having applied the statistical problem to a certain
number of experiments, it is tried to determine which one of the two is the true hypothesis. H0 is
called the null hypothesis, the hypothesis that wants to be compared. A null hypothesis is a statis-
tical hypothesis that is tested for possible rejection under the assumption that it is true (usually
that observations are the result of chance).
In statistical hypothesis testing, the critical value is the value corresponding to a given signifi-
cance level. This cut-off value determines the boundary between those samples resulting in a test
statistic that leads to the rejection of the null hypothesis and those that lead to a non-rejection of
the null hypothesis. A process that is commonly used:
• Compute from the observations the observed value tobs of the test statistic T.
• Calculate the p-value (critical value). This is the probability, under the null hypothesis, of
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sampling a test statistic at least as extreme as that which was observed.
• If and only if the p-value is less than the required significance level (the selected probability),
then we say the null hypothesis (H0) is rejected at the given level of significance in favor
of the alternative hypothesis (H1). Therefore, the conclusion is the rejection of the null
hypothesis.
In the case that the p-value (critical value) is not less than the required significance level,
then the test has no result. The evidence is not sufficient to reach a conclusion and you may
reject the null hypothesis at the pre-specified level of significance.
Statistics are helpful in analyzing most collections of data. This is equally true of hypothesis test-
ing which can justify conclusions even when no model of the data exists.
Applying this theory in the thesis, the following concepts will be needed: Consider the signed
human drug-target network. For the drug pair (i, j), let cij be the number of targets in common,
split into c++ij , c
−−
ij and c
+−
ij according to the signs of the corresponding drug-target edges. Denote
ξ = c++ij + c
−−
ij the total number of coherent edge pairs for the drug pair, and
ρ =
∑
i,j
(
c++ij + c
−−
ij
)∑
i,j cij
(2.1)
the probability of an edge pair to be coherent over the entire network. Then the probability of
drawing at most ε coherent edge pairs out of cij edge pairs is the cumulative binomial
P [x ≤ ξ] =
ξ∑
`=0
 cij`
 (1 − ρ)` · ρcij−`. (2.2)
If α = 0.05 is the threshold for statistical significance (statistical level), when the p-value 1−P [x ≤
ξ] < α the drug pair (i, j) is enriched for coherent actions. A similar calculation applies also for
the significance of the incoherent actions of the pair (i, j).
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2.5 Adjacency Matrix
Sometimes it is convenient to represent a graph by a matrix. The most important matrix associ-
ated to a graph is the so called adjacency matrix. The adjacency matrix of the graph G = (V , E) is
an n × n matrix A = (aij), where n is the number of vertices in G, V = v1, ..., vn and aij = number
of edges between vi and vj .
In particular, aij = −1, 1 if there is and edge between the i-th and j-th vertices, and aij = 0
otherwise. When the graph is undirected the matrix A is symmetric, i.e. AT = A. We are going
to represent the drug-target network through a matrix, which we call the drug-target network
matrix, and which can be used to form the adjacency matrix.
Atd =

a11 a12 . . . a1m
a21 a22 . . . a2m
...
...
. . .
...
ap1 ap2 . . . apm

pxm
(2.3)
Where
m = number of drugs
p = number of targets
n = m + p = total number of nodes
In the matrix including all the organisms, we have 6699 different drugs and 4139 different tar-
gets. However, we will use only some of them as some targets have no known action.
aij = −1, 0, 1 ∀i = 1, . . . , p; j = 1, . . . , m
The values of aij can be -1,0 or 1 depending on the action that an specific drugs has on an specific
target.
aij = 1 The drug j acts as an activator to the target i.
aij = −1 The drug j acts as an inhibitor to the target i.
aij = 0 The drug j has not known action on the target i ([]) or the action cannot be classified as
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’activator’ or ’inhibitor’.
Once we have this drug-target network matrix we can create the adjaceny matrix. This matrix
is a means of representing which vertices (or nodes) of a graph are adjacent to which other ver-
tices.
A =
 0 AtdATtd 0

nxn
=

0 0 . . . 0 a11 a12 . . . a1m
0 0 . . . 0 a21 a22 . . . a2m
...
...
. . .
...
...
...
. . . . . .
0 0 0 0 ap1 ap2 . . . apm
a11 a21 . . . ap1 0 0 0 0
a12 a22 . . . ap2 0 0 . . . 0
...
...
. . .
... 0
...
. . .
...
a1m a2m . . . apm 0 0 . . . 0

nxn
(2.4)
One can see that this matrix is symmetric, that is because we are working with an undirected
graph, that means a graph in which edges have no orientation.
Moreover, as we are dealing with a bipartite graph we can see zeros in the upper-left and bottom-
right side of the matrix. That means there will never be a connection between two drugs or
between two targets.
As an example, we can transform the network in Fig. 2.5 to its drug-target network matrix.
In this example number of drugs = m = 4, number of targets = p = 2 and number of nodes
= n = m + p = 6. It can also be seen that the number of edges in this case is 4 (number of lines
joining drugs and targets). Then, considering that i = 1, 2 and j = 1, 2, 3, 4, one can see that:
• a11 = −1 (edge joining drug ’DB00001’ and target ’BE0000048’),
• a12 = −1 (edge joining drug ’DB00006’ and target ’BE0000048’),
• a23 = 1 (edge joining drug ’DB00009’ and target ’BE0000211’),
• a24 = 1 (edge joining drug ’DB00086’ and target ’BE0000211’)
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Atd =
a11 a12 a13 a14a21 a22 a23 a24

2x4
=
−1 −1 0 00 0 1 1

2x4
(2.5)
Now, we can pass from the drug-target network matrix to the adjacency matrix.
A =
 0 AtdATtd 0

6x6
=

0 0 a11 a12 a13 a14
0 0 a21 a22 a23 a24
a11 a21 0 0 0 0
a12 a22 0 0 0 0
a13 a23 0 0 0 0
a14 a24 0 0 0 0

6x6
=

0 0 −1 −1 0 0
0 0 0 0 1 1
−1 0 0 0 0 0
−1 0 0 0 0 0
0 1 0 0 0 0
0 1 0 0 0 0

6x6
(2.6)
Some data of the different matrices used in this thesis (considering Human, Yeast and E.Coli) are
Figure 2.5: Same representation as Fig. 2.1 only considering classifiable actions.
shown in Table 2.7.
Organism Edges of Atd Matrix Atd Matrix size (targets x drugs) Adjacency Matrix size
’All’ 4624 997x1513 2510x2510
’Human’ 4152 824x1337 2161x2161
’Yeast’ 21 8x19 27x27
’Escherichia coli’ 141 50x69 119x119
Table 2.7: Number of edges. The adjacency matrix will have double number of edges than
the Atd matrix.
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2.6 Programming method
In order to manage and modify all the information present in the DrugBank database some infor-
matic tool had to be used. The program choosen to do so is Matlab program as we consider it a
good option for its clarity and suitability for this thesis. New constructed Matlab code suited for
this specific database was used.
Once all the useful information was extracted from the DrugBank database, to calculate the data
shown in the tables in the Results section we used self-generated Matlab code. Similarly, new
constructed Matlab code was used to generate the plots shown in the Results section.
This code was constructed using toolboxes such as Statistics and Machine Learning Toolbox or
Bioinformatics Toolbox to process the data.

3
Results
A drug-target network is constructed using the DrugBank database (version 4.3, downloaded
November 2015). It is a bipartite graph having two classes of nodes: drugs and targets. The edges
represent known actions of a drug on its targets.
Total Human Pharmacological Action E. Coli Yeast
’n. of drugs’ 6699 4932 1367 655 39
’n. of targets’ 4139 2350 701 368 14
’total number of edges’ 16386 11180 2942 982 41
’n. of signed edges’ 4624 4152 2623 141 21
’n. of edges without sign’ 11762 7028 319 841 20
Table 3.1: Human, E.coli and Yeast drug-target network. About 68% of the total of Drug-
Bank drug-target interactions are associated to human targets, about 6% to E.coli targets and
about 0.25% to Yeast targets.
Selecting only human targets, a subnetwork can be extracted. It is on this subnetwork that the
thesis is mainly focused.
Consider this human drug-target network reconstructed from the DrugBank database, and asso-
ciate to its edges a sign according to the action that every drug has on its target as seen in Table
2.1. Table 3.2 reports the resulting sign distribution. Looking at the drug degree distribution
in Fig. 3.1, one can see that the drugs that have a greater amount of unclassifiable actions (blue
bars) are those with higher connectivity, while the situation is much improved for drugs with
lower connectivity. Comparing the drug (Fig. 3.1) and target (Fig. 3.2) connectivity analysis, the
latter has a significant difference in the fact that also targets with high connectivity tend to have
a certain fraction (even higher that 50%) of edges having a known sign. In the drug connectivity
histogram, on the other hand, when a drug has signed edges, then they are almost all of the same
sign, see Fig. 3.3.
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Human Pharmacological Action E. Coli Yeast
’n. of drugs’ 1337 1202 69 19
’n. of targets’ 824 582 50 8
’n. of positive edges’ 1417 1093 4 0
’n. of negative edges’ 2735 1530 137 21
Table 3.2: Human, E.Coli and Yeast drug-target network having discarded unclassifiable
actions. Considering the human case, the fraction of edges which cannot be assigned a sign
is around 63%, this can be seen graphically in Fig. 3.1. The fraction decreases drastically if
we restrict to actions which can be classified as pharmacological, to less than 11%, this can
be seen graphically in Fig. 3.9. Considering the E.Coli case, the fraction of edges without
sign higher than in the human case, about 86%. This can be seen graphically in Fig. 3.5.
Figure 3.1: The plot shows the number of human targets associated to each drug. In green
and red are respectively the number of targets for which the mode of action can be classified
as positive (green) and negative (red). The upper plot shows the number of targets for which
the mode of action can not be classified (blue).
Figure 3.2: The plot shows the number of drugs associated to each human target. In blue the
the number of drugs for which the mode of action can not be classified is shown, while in
green and red are respectively the number of drugs with positive (green) and negative (red)
modes of action.
This same analysis is made for the E.Coli and Yeast case. Looking at the drug degree distribu-
tion of E.Coli in Fig. 3.5, one can see that the drugs with a large amount of unclassifiable actions
(blue bars) have a higher connectivity, while the situation does not improve for drugs with lower
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Figure 3.3: Drug connectivity histogram: Shows the same quantities as Fig. 3.1 but only for
the 50 drugs having the highest total number of targets in DrugBank.
Figure 3.4: Target connectivity histogram: Shows the same quantities as Fig. 3.2 but only for
the 50 targets having the highest total number of drugs in DrugBank.
connectivity. The fraction of positive actions is only about 3% whereas the fraction for unknown
action is about 86%.
Figure 3.5: The plot shows the number of E.Coli targets associated to each drug. In green
and red are respectively the number of targets for which the mode of action can be classified
as positive (green) and negative (red). The upper plot shows the number of targets for which
the mode of action can not be classified (blue).
In the Yeast case, few data is available but one can see in Fig. 3.7 that the drugs with higher
connectivity are all of negative sign and do not have any positive action in any of the drugs.
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Figure 3.6: The plot shows the number of drugs associated to each E.Coli target. In blue the
the number of drugs for which the mode of action can not be classified is shown, while in
green and red are respectively the number of drugs with positive (green) and negative (red)
modes of action.
Figure 3.7: The plot shows the number of Yeast targets associated to each drug. In green and
red are respectively the number of targets for which the mode of action can be classified as
positive (green) and negative (red). The upper plot shows the number of targets for which
the mode of action can not be classified (blue).
Figure 3.8: The plot shows the number of drugs associated to each Yeast target. In blue the
the number of drugs for which the mode of action can not be classified is shown, while in
green and red are respectively the number of drugs with positive (green) and negative (red)
modes of action.
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3.1 Combinatorial analysis restricted to pharmacological drug
pairs.
If not explicitly stated otherwise, the analysis is referred for the Human organism. The anal-
ysis carried out in the previous section for all signed drug-target interactions is here repeated
restricting to the signed pharmacological drug-target pairs (see Tables 3.1 and 3.2 for a quantifi-
cation). Fig. 3.9 and 3.10 shows the equivalent drug and target connectivity analysis restricted
Figure 3.9: Drug connectivity analysis on the human network (pharmacological actions).
The same quantities as in Fig. 3.1 are shown, limited to the edges that have a known phar-
macological action. The number of targets per drugs (Fig. 3.1) is now smaller, and almost all
of them have a sign.
Figure 3.10: The target connectivity for pharmacological actions.
to edges representing pharmacological actions. In both cases the connectivity decreases consid-
erably when we compare it with Fig. 3.1 and 3.2, and the already mentioned fact that most
pharmacological actions have a known sign (see Table 3.1) allows us to have a sharper picture
of the sign distributions. For both drugs and targets, in fact, the sign distribution tends to be
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Figure 3.11: Drug connectivity histogram (pharmacological actions): Shows the same quan-
tities as the left Fig. 3.9 but only for the 50 drugs having the highest total number of targets
in DrugBank. Notice how the action of a drug on its targets is often only positive or only
negative.
Figure 3.12: Target connectivity histogram (pharmacological actions): Shows the same quan-
tities as right Fig. 3.10 but only for the 50 targets having the highest total number of drugs
in DrugBank. Often, but not always, there is a neat majority of drugs acting with the same
sign.
“monochromatic”, i.e., most edges adjacent to a drug or to a target tend to be positive or negative
but rarely both, see plots in Fig. 3.11 and 3.12.
In the E.Coli case, one can see in Fig. 3.13 that the unknown actions decrease drastically when
only considering pharmacological actions (from 86% to about 7%). Almost all of the actions are
of negative sign (about 91%).
In the Yeast case, one can see in Fig. 3.15 that the unknown actions decrease considerably when
only considering pharmacological actions (from 49% to 0%). All of the actions are of negative
sign.
When restricting the human drug-target network to signed edges, we obtain a bipartite signed
graph involving 1337 drugs and 824 targets, containing 1417 positive and 2735 negative edges,
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see Table 3.1. The drug-target network described in Table 3.1 has one very large connected compo-
nent involving 81% of the drugs and 71% of the targets, plus a number of other smaller connected
components, see Fig. 3.17.
Figure 3.13: Drug connectivity analysis on the E.Coli network (pharmacological actions).
The same quantities as in Fig. 3.5 are shown, limited to the edges that have a known phar-
macological action.
Figure 3.14: Target connectivity analysis on the E.Coli network (pharmacological actions).
The same quantities as in Fig. 3.6 are shown, limited to the edges that have a known phar-
macological action.
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Figure 3.15: Drug connectivity analysis on the human network (pharmacological actions).
The same quantities as in Fig. 3.7 are shown, limited to the edges that have a known phar-
macological action.
Figure 3.16: Target connectivity analysis on the human network (pharmacological actions).
The same quantities as in Fig. 3.8 are shown, limited to the edges that have a known phar-
macological action.
Figure 3.17: Connected components of the signed drug-target network. The main plot
shows that the network has a very large connected component (of size 1667, of which 1079
drugs and 588 targets out of a total of 1337+824=2161 nodes). It has then other 135 smaller
connected components, whose number of drug/targets can be seen in the inset plot (at least
for those of dimension larger than 2).
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3.2 Combinatorics of signed drugs.
The classification of drug actions into positive and negative modes of action allows us to charac-
terize the effect of multiple drugs acting on the same target. Two drugs sharing the same target
tend to reinforce their effect on the target if their modes of action have the same sign, while they
tend to mitigate the overall effect if the signs are different. The 3 possible sign combinations of a
drug pair on a common target, (+, +), (-, -), and (+, -) are shown in Fig.3.18. The two combinations
(+, +) and (-, -) will be referred to as coherent, as the action of a drug is reinforced by the presence
of a second drug. In the remaining combination (+, -), instead, the presence of a second drug
tends to counteract (and hence in general reduce) the action of the first drug. We will call this
configuration incoherent. Some statistics on pairs of drugs sharing at least a common target are
Figure 3.18: Coherent/incoherent actions of drug pairs. When two drugs act simultane-
ously on the same target, their action can be coherent (i.e., the second drug tends to reinforce
the action of the first) or incoherent (i.e., the second drug tends to counteract the action of
the first).
shown in Fig. 3.19. Summing up the data of the top left subpanel of Fig. 3.19, the total number
of drug pairs incident to at least a common target is 25564 (sum af all bars). The number of drug
pairs having exactly one target in common is 16050 (highest bar). The statistics for the three pairs
of edge sign combinations (+, +), (-, -) and (+, -) are reported in the remaining 3 subpanels of the
same Figure. As can be seen in the bottom right subpanel, incoherent drug actions are not rare in
the human drug-target network. The total number of drug pairs acting incoherently on at least
one target is 6462 (sum of all bars). These drug pairs act incoherently on a total of 10594 targets
(cumulative sum of all bars).
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Figure 3.19: Coherent/incoherent actions of drug pairs. Drug pairs with common targets,
and their sign patterns. All histograms show the number of drug pairs having one or more
targets in common (the number of common targets is on the horizontal axis). Only signed
edges are considered. Top left subpanel: all pairs of drugs having one or more common tar-
gets, and considered regardless of sign. Top right subpanel: only positive/positive actions
(both drugs act positively on the target). Bottom left subpanel: only negative/negative ac-
tions. Bottom right subpanel: positive/negative actions. The totals refer to the total number
of simple drug-drug-target interactions.
The corresponding numbers for coherent actions (upper right (+,+) and bottom left (-,-) subpan-
els) are however much higher: 20404 drug pairs act coherently on at least one target (sum of all
bars in (-,-) and (+,+) plots), for a total number of coherent actions of 37542 (cumulative sum of
all bars in (-,-) and (+,+)).
In the case of E.Coli, as mentioned before, only 3% of the total actions were positive, therefore,
almost all drug pairs (246) are coherent negative (-,-), while one only case is coherent positive
(+,+). In the Yeast case, as all of its actions are negative, a straightforward conclusion is that all
drug pairs (79) will be coherent negative (-,-).
The shortcoming of the analysis carried out so far is that even after restricting to signed actions,
56% of the 1337 drugs have 2 or more targets, hence when we look at multiple drugs applied
simultaneously it is necessary to investigate their effect on all of their common targets.
As can be seen in Fig. 3.19 (top left subpanel), around 5000 drug pairs share 2 targets, and more
than 2000 have 3 targets in common, while other 2405 pairs have more than 3 targets in common.
The simplest possible approach to tackle this more complex problem consists in looking at all
cycles of length 4 formed by two drugs having at least 2 targets in common.
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Figure 3.20: Coherent/incoherent actions of drug pairs (pharmacological actions). Anal-
ogous of Fig. 3.19(b), but restricted to signed pharmacological interactions.
Three qualitatively different classes of length-4 cycles can be identified, which we call (fully) co-
herent, mixed and (fully) incoherent. They are shown in Fig. 3.21. Coherent cycles are those for
which both drugs act with the same sign on each of the targets, hence reinforcing each other’s
action on both targets. In incoherent cycles, instead, the signs of the drug actions are conflicting
on both targets, leading to mitigation of the effect on both targets. Mixed cycles occur when the
action of a drug pair has the same sign on one of the targets but conflicting signs on the other
target (i.e., coherent on one target but incoherent on the other). As can be seen on Table 3.3, the
fraction of coherent length-4 cycles is around 81% of the total, while that of incoherent length-4
cycles is 13.5%. Mixed cycles are the most rare (around 5.5%). Notice how fully coherent and
fully incoherent length-4 cycles are positive, i.e., they have an even number of negative edges,
while mixed cycles are negative (odd number of negative edges). Hence, overall, the fraction of
positive length-4 cycles is around 94.5% of the total, see Table 3.3.
In the E.Coli case, only about 3% of the actions are positive (having already discarded the un-
known actions) as can be seen in Fig. 3.5, it is not strange to see that all cases (648) are Coherent
(-,-/-,-).
In the Yeast case, as there are only 21 signed edges as seen before in Table 3.1, no 4-length cycle
of any type can be formed.
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Figure 3.21: Coherent/mixed/incoherent length-4 cycles. Two drugs having two targets in
common in a signed graph. In panel (a) all 3 cases lead to an (undirected) positive 4-edged
cycle, and the drug actions are coherent at both targets. In panel (b) instead, the length-4
(undirected) cycle is negative, and the action of the drugs is incoherent on one of the two
targets but coherent on the other. In panel (c) the action of the drugs is incoherent on each
target, but the cycle is positive.
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Figure 3.22: Mixed (+,+/+,-). The plot shows the drugs that have a large amount of cases in
this particular mixed 4-length cycle. The 6 drugs that appear in most cases are: Cabergoline,
Bromocriptine, Lisuride, Pergolide, Ropinirole, Apomorphine.
Figure 3.23: Mixed (+,+/+,-). The same plot as Fig. 3.22 considering only pharmacological
actions. The drug that appear in most cases is Flumazenil.
Considering the Mixed (+,+/+,-) case, a total of 130 drugs are present in at least one of the
1138 cases of this 4-length cycle. As it can be seen in Fig. 3.22, 4% (6 drugs) of the drugs are
present in more than the 44% of the cases. Taking a closer look into this 6 drugs, all of them are
indicated for the treatment of the symptoms of Parkinson’s disease.
Similarly, in the Coherent (+,+/-,-) case, a total of 100 drugs are present in at least one of the
6084 cases of this 4-length cycle. As it can be seen in Fig. 3.24, 15% (15 drugs) of the drugs are
present in more than the 86% of the cases. Taking a closer look into this 15 drugs, all of them
can be classified in the Diazines class and Pyrimidines and pyrimidine derivatives subclass. The
predominant indications for this drugs (53%) are for the treatment of insomnia, in other words,
used as a relaxant and sedative. Some other (20%) of this 15 drugs are indicated for the treatment
of epilepsy.
Making the same study but only considering the interactions with a pharmacological actions we
can see some clear differences between Figures 3.22 and 3.24 (pharmacological actions+non/unknown
34 3 Results
Balanced cases Number of cases
coherent (+,+/+,+) 25158
coherent (+,+/-,-) 3042
coherent (-,-/-,-) 28166
mixed (+,+/+,-) 1138
mixed (+,-/-,-) 2658
incoherent (+,-/+,-) 9375
Table 3.3: Coherent and incoherent length-4 cycles.
pharmacological actions) and Figures 3.23 and 3.25 (only pharmacological actions). In the Mixed
(+,+/+,-) case we can observe that one drug (Flumazenil, DB01205) is very present in the 25%
of the cases while all the other drugs have a minor representativeness (6.7% or less). The dis-
tribution of all the drugs also changes completely, for example the drug Cabergoline(DB00248),
that was the most representative drug in most cases, when considering only pharmacological ac-
tions, disappears from the plot. Even if it was present in many cases, none of them had a known
pharmacological action.
Figure 3.24: Coherent (+,+/-,-). The plot shows the drugs that have a large amount of cases
in this particular mixed 4-length cycle. The 15 drugs that appear in most cases are: Pento-
barbital, Butalbital, Talbutal, Metharbital, Primidone, Secobarbital, Thiopental, Methylphe-
nobarbital, Amobarbital, Aprobarbital, Butethal, Heptabarbital, Hexobarbital, Barbital and
Barbituric acid derivative.
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Figure 3.25: Coherent (+,+/-,-). The same plot as Fig. 3.24 considering only pharmacolog-
ical actions. The 6 drugs that appear in most cases are: Isoflurane, Sevoflurane, Desflurane,
Methamphetamine, Enflurane and Ephedra. It can be clearly seen the change in the dis-
tribution of the drugs, none of the most representative drugs is in both Fig. 3.24 and this
plot.
Figure 3.26: Mixed (+,-/-,-). The plot shows the drugs that have a large amount of cases in
this particular mixed 4-length cycle. The 4 drugs that appear in most cases are: Cabergoline,
Paliperidone, Bromocriptine and Trimipramine.
Figure 3.27: Mixed (+,-/-,-). The same plot as in Fig. 3.26 restricting only to pharmacological
actions. It can be seen as in the other 4-length cycles that the drug distribution changes
drastically from the Fig. 3.26 to this one.
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Figure 3.28: Incoherent (+,-/+,-). The plot shows the drugs that have a large amount of
cases in this particular incoherent 4-length cycle. The 4 drugs that appear in most cases are:
Pergolide, Bromocriptine, Apomorphine and Ropinirole.
Figure 3.29: Incoherent (+,-/+,-). The same plot as in Fig. 3.28 restricting only to pharma-
cological actions.
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3.3 Connectivity analysis of drug pairs: distribution of
coherent/incoherent actions.
With a total of 48136 targets being acted upon by at least two drugs, a natural question to ask is
if such pairwise connectivity is high or low with respect to a null model having the same drug
edge distribution. Comparing with a null model, obtained maintaining the same edge distribu-
tion (sign included) at the drug side, but reassigning randomly the edges to the targets, then the
drug-target topological properties one obtains are drastically different.
On a null model, the number of drug pairs sharing at least a target reduces from 25564 to
10194.49 (average over 100 realizations of the null model) and so does the total number of drug
pairs incident to a common target, from 48136 to 10451.52. We deduce that the signed drug-
target network is highly organized, and in particular highly redundant in its coverage of the
targets.
For instance, the original target connectivity is such that only near half (407) of the 824 targets
are hit by more than one drug, while in a null model this number is around 95%. However, the
target edge distribution for the null model completely lacks the highly connected nodes which
can instead be seen in Fig. 3.2. As can be seen in Fig. 3.30, the consequence is that in null models
a pair of drugs very seldom exceeds a total of 3 common targets, counting both coherent and inco-
herent actions (green bars). In the true drug-target network, instead, edges tend to concentrate on
fewer targets, leading to abundance of targets shared by more than two drugs (in Fig. 3.30 green
bars for the null model should be compared to all the other bars taken together, representing the
original network).
Also the sign distribution in the true drug-target network is highly non-random. If 78.7% of the
drug pairs hitting a common target have a coherent action, such number is drastically less in
our null models, around 55.04%, meaning that in the real drug-target network not only known
drugs tend to hit always the same targets, but they tend to do so with the same sign, leading to
an overabundance of coherent joint actions. In spite of the limited frequency, also the fraction of
incoherent drug pair actions is far from being negligible.
As can be seen on Fig. 3.30, the histogram with counts of coherent and incoherent actions of drug
pairs is highly skewed and has two tails: just like many drug pairs act coherently on many targets,
there exists a considerable number of drug pairs having an incoherent action simultaneously on
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Figure 3.30: Distribution of coherent/incoherent edge pairs. The red/grey/blue bars of
the histogram represent counts of the coherent and incoherent actions of the drug pairs
on common targets. The histogram is significantly skewed, meaning that many drug pairs
tend to have an abundance of coherent actions or of incoherent actions, rather than of both
simultaneously. When the overabundance is statistically significant (binomial cumulative
distribution test, p-value of 0.05, see Background Material (Statistical hypothesis testing)),
then the bars are coloured: red for overabundance of coherent actions, blue for incoherent
actions. The green bars overlaying to the other bars represent the distribution of the coher-
ent/incoherent actions for the null model. For nearly all drug pairs, nonzero green bars reach
at most 4 targets in common, counting together coherent and incoherent actions, i.e., the two
tails are absent in a null model.
multiple targets, for instance pairs of drugs in which one of the two activates all its targets while
the other inhibit them. The blue bars in Fig. 3.30 correspond to pairs whose incoherent action
is statistically significant, given the total amount of pairs and its coherent/incoherent partition
(cumulative binomial test, see Background Material (Statistical hypothesis testing)). Since the
number of coherent action pairs is much higher, statistical significance for them requires a pair
to hit coherently a larger number of targets (red bars).
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3.4 Synergistic/compensatory pharmacological effect of drug
pairs.
Most drugs are designed to produce a specific action on selected targets, here denoted pharmaco-
logical targets. Other targets of the same drug (here called off-targets) are often present but they
are normally undesired. We refer to these off-targets as the side effect of the drug.
Let ti be the number of targets associated to the i-th drug for which the sign of the action is
available and pi , pi ≤ ti , the number of signed pharmacological targets of drug i. Let further be
cij the number of common (signed) targets of the drug pair (i, j), and pij , pij ≤ cij , the number
of (signed) pharmacological targets shared by (i, j). Denote si = ti − pi the number of (signed)
off-targets of drug i and sij = cij − pij the number of (signed) off-targets in common between i-th
and j-th drugs. To specify the sign of the action we will use upper indices: p++ij , p
−−
ij and p
+−
ij (re-
spectively s++ij , s
−−
ij and s
+−
ij ). Here we are assuming that the coherent pairs p
++
ij and p
−−
ij enhance
the action of each single drug on the common pharmacological targets (i.e., act synergistically),
while in an incoherent pair p+−ij the actions of the two drugs tend to counteract each other (i.e.,
the action is compensatory).
Consider the case pij > 0 and sij = 0, i.e., the two drugs share only common pharmacological tar-
gets. Fig. 3.31 tells us that for pharmacological actions the distribution of coherent/incoherent
interaction pairs has a longer tail towards the coherent end, but does not tell us what fraction
of pharmacological targets of a drug i receives a benefit from the presence of a second drug j
sharing a certain number of pharmacological targets with it. In order to quantify this, we use the
synergistic score coefficient ai(j).
If pij is the number of signed pharmacological targets shared by the drugs i and j (split, according
to the signs, into p++ij , p
−−
ij and p
+−
ij , such that p
++
ij + p
−−
ij + p
+−
ij = pij), then the synergistic score
coefficient is defined as
ai(j) =
p+−ij − (p++ij + p−−ij )
pi
(3.1)
Since pij ≤ pi , it must be ai(j) ∈ [-1, 1], and, by construction, sign(ai(j)) = sign(aj(i)).
ai(j) > 0 means that more coherent than incoherent actions are established on the pharmacolog-
ical targets of drug i by the presence of a second drug j. Since ai(j) > 0 if and only if aj(i) > 0,
this synergistic effect is always mutual, although ai(j) , aj(i) when the two drugs have a differ-
ent number of pharmacological targets. Negative synergistic score mean that for a drug pair the
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incoherent actions are more numerous than the coherent ones. Clearly ai(j) < 0 if and only if
aj(i) < 0.
Of the 14380 drug pairs with common pharmacological targets, 10611 have pij > 0 and sij = 0,
hence for them we can compute ai(j). The synergistic score coefficient is positive in 81.6% of the
cases. In 45.2% of the cases it is ai(j) ≥ 0.5 and aj(i) ≥ 0.5, i.e., a significant mutual synergistic
score is produced, while in 29.8% of the cases ai(j) ≥ 0.5 but not aj(i). There are 70 cases in
which ai(j) = aj(i) = 0, and 1882 cases in which both ai(j) and aj(i) are <0. The histogram of the
synergistic score coefficients is shown in Fig. 3.32. When classifying the common targets of drug
Figure 3.31: Coherent/incoherent edge pairs distribution (pharmacological actions). The
red/grey/blue bars of the histogram represent counts of the coherent and incoherent ac-
tions of the drug pairs on common pharmacological targets. The histogram is significantly
skewed, meaning that many drug pairs tend to have an abundance of coherent actions or
of incoherent action rather than of both simultaneously. When the overabundance is sta-
tistically significant (binomial cumulative distribution test, p-value of 0.05, see Background
Material (Statistical hypothesis testing)), then the pairs are coloured: red for overabundance
of coherent actions, blue for incoherent actions. Notice the presence of a long tail towards
the coherent actions (red bars). The green bars overlaying to the other bars represent the
distribution of the coherent/incoherent actions for the null model. For nearly all drug pairs,
nonzero green bars reach at most 4 targets in common, counting together coherent and inco-
herent pharmacological actions, i.e., the tail of coherent pairs is absent in a null model.
pairs according to principal targets and off-targets, it can be observed that in the vast majority of
cases in which drug pairs share common pharmacological targets then have no common off-target,
meaning that the synergistic score coefficient describes the entire overlap of the pair.
For many of the pairs with significantly large synergistic score sharing one or more common
pharmacological targets, experimental evidence of synergistic action is available. For instance,
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Figure 3.32: Synergistic scores for drug pairs and pharmacological targets. The histogram
shows the distribution of synergistic score coefficients for drug pairs sharing one or more
pharmacological targets and no off-targets. When ai(j) > 0 and aj(i) > 0, the two drugs
induce a benefit on each other’s pharmacological targets, i.e., the number of coherent action
pairs is bigger than the number of incoherent ones (81.6% of the cases).
the pair of DNA Antimetabolites Gemcitabine and Fludarabine share an inhibitory action on
Ribonuceotide Reductase, hence we classify them as synergistic. They are known to act synergis-
tically as anticancer agents in Acute Myeloid Leukemia [6]. For others, there is no documented
improvement by the simultaneous application of the two drugs. For instance, Panitumumab and
Cetuximab are both targeting the epidermal growth factor receptor, and used for treating EGFR-
expressing metastatic colorectal cancers. In our metric the synergistic scores of the pair are both
1, just based on the common target. In other cases the improvement, as measured by the syner-
gistic score, is positive but low because of the limited overlap among the pharmacological targets.
One example among many is the pair Propofol and Sevoflurane. Both have the GABAA receptor
among their pharmacological targets.
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3.5 Side effect improvement/aggravation through drug
combinations.
When two drugs share pharmacological targets but also off-targets, it becomes interesting to un-
derstand if it is possible to combine drugs so as to reduce their side effect. The principle that
we follow is to look for drug pairs having a positive synergism on common pharmacological tar-
gets and incoherent actions on common off-targets. As incoherent actions correspond to opposite
edge signs, they tend to compensate each other, hence the side effect tends to be mitigated. Let
us consider drug pairs such that pij > 0 and sij > 0, i.e., having some pharmacological target and
some off-target in common. In particular, we look for drug combinations in which
1. the actions on the pharmacological targets are predominantly coherent: p++ij + p
−−
ij > p
+−
ij ;
2. the actions on off-targets tend to cancel each other: s+−ij > s
++
ij + s
−−
ij
To quantify the benefit of adding a second drug j on the side effect of drug i, we consider the side
effect score coefficient bi(j).
Let si be the side effect of the i-th drug, i.e., the number of human targets that are not classified in
DrugBank as pharmacological targets. If sij is the number of common targets of the drug pair (i,
j) which are not pharmacological targets, s++ij , s
−−
ij and s
+−
ij specify theirs signs, then the side effect
score coefficient is defined as
bi(j) =
s+−ij − (s++ij + s−−ij )
si
(3.2)
By construction, sign(bi(j)) = sign(bj(i)) and −1 ≤ bi(j) ≤ 1 , with bi(j) < 0 meaning an aggravat-
ing effect of the drug j on the side effect of i, bi(j) = 0 meaning neutral effect in the side effect
(s+−ij = s
++
ij + s
−−
ij , see Fig. 3.33), and bi(j) > 0 meaning an improvement of the side effect of drug
i due to drug j, see Fig. 3.34. In particular, bi(j) = 1 means that the drug j hits all off-targets of
drug i with an action which is opposite in sign to that of drug i. Notice that by construction bi(j)
and bj(i) must have the same sign, meaning that for drug pairs with a positive side effect score the
benefits are always mutualistic. Screening the 14380 drug pairs having pharmacological targets
in common, we obtain 325 pairs. Among these, 205 pairs are beneficial i.e., have bi(j) > 0 and
bj(i) > 0; 39 are neutral, i.e., have bi(j) = bj(i) = 0 and 81 are aggravating, i.e., bi(j) < 0 and
bj(i) < 0. The distribution of their side effect score coefficients bi(j) is shown in Fig. 3.35. For a
significant fraction of drug pairs (56 out of 205), both coefficients bi(j) and bj(i) are ≥ 0.5, mean-
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ing that the drugs i and j have a significant reciprocal beneficial effect on each other’s side effect.
Several more cases (81) are obtained in which bi(j) ≥ 0.5 for one of the 2 drugs, although not for
both. These cases with "unilateral" side effect improvement often correspond to cases in which
one drug has a large side effect (in terms of number of off-targets) and the other drug a small side
effect, see Fig. 3.34. Hence when the latter drug is added to the former it can only improve on a
few of its many off-targets.
Figure 3.33: Side effect quantification for drug pairs. The target in green is a common
pharmacological target. The action of the two drugs on it (thick red arrows) is coherent and
reinforces the effect. All other targets are off-targets and constitute a side effect for the two
drugs. The two drugs share 2 off-targets. In one of them the simultaneous presence of the
two drugs tends to mitigate the effect, while in the other the two drugs act with the same
sign, hence the side effect on it is aggravated. Overall the drug 1 experiences a side effect
improvement on 50% of its off-targets but an aggravation on the remaining 50%, while for
drug 2 the beneficial/aggravating effect is only on 33% of the off-targets. For both however,
the side effect score is equal to 0: b1(2) = b2(1) = 0.
Figure 3.34: Side effect quantification for drug pairs. The target in green is a common
pharmacological target. The action of the two drugs on it (thick red arrows) is coherent and
reinforces the effect. All other targets are off-targets and constitute a side effect for the two
drugs. The side effect on the off-target in common is reduced by the combination of drugs.
For drug 1, b1(2) = 0.5, while for drug 2 it is b2(1) = 0.25, because of the higher number of
off-targets.
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Figure 3.35: Side effect quantification for drug pairs. The histogram shows the side effect
score coefficient for all drug pairs having a positive synergistic score on the common phar-
macological targets. For 63% of the resulting pairs the side effect score is positive, while it is
negative for 25% of pairs and neutral in the remaining cases (bar in the origin, representing
cases in which s+−ij = s
++
ij + s
−−
ij ). For a significant fraction of pairs (17%) the mutual benefit
is at least 50% (i.e., bi(j) ≥ 0.5 and bj(i) ≥ 0.5). The number increases if we look at pairs in
which at least one of the two drugs has a 50% improvement (42% of pairs).
4
Conclusions and Future work
A drug-target network contains valuable information for researchers interested in network phar-
macology and drug combinatorics. This has to do not only with the biochemical classification
of the drug compounds and with the therapeutical classification of the molecular targets, but
also with the functional classification of the modes of action of the drugs. In order to explore
systematically this aspect, we have to introduce a coarse-grained classification of the mechanisms
of action. Such a "binary" classification covers a significant fraction of the known categories for
drug-target modes of action.
The fact that many human drug-target interactions cannot be classified in terms of action signs
is certainly a limitation of the present study and of the approach in general. The fact that the
number of such unsigned edges decreases so drastically when we zoom on pharmacological tar-
gets (passing from 63% to 11%) suggests that our results should give reliable predictions on the
coherence/incoherence of drug pairs on the "primary" pharmacological targets (and hence on
their potential synergies), but could have a limited predictability power on the effective side ef-
fect score, when many other unsigned interactions are shared by a pair of drugs alongside the
coherent/incoherent off-targets we consider here.
Having so few unsigned pharmacological drug-target interactions also suggests that the modes
of action that can be characterized with signs are more "valuable" in terms of describing the ther-
apeutical effects of a drug. Hence also the investigation of the amount of coherence/incoherence
encoded in this subset of signed pharmacological interactions is important. An analysis like the
one carried out in Figs. 3.1, 3.2, 3.19 and 3.30 is repeated for the subnetwork of signed phar-
macological targets (see Figs. 3.9, 3.10, 3.11, 3.20 and 3.31). It turns out that some of the prop-
erties mentioned for the entire signed drug-target network still hold for the signed subnetwork
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of pharmacological actions. For instance, the long tail of coherent action pairs observed in the
distribution of Fig. 3.30 is still visible in Fig. 3.31, much more than the corresponding incoherent
tail, in accordance with the high synergistic score we found.
For what concerns the drug pairs in influencing each other’s side effect, their number is remark-
ably low. This is probably due to the fact that often times when sij > 0 the synergistic score ai(j)
is negative, i.e., the pair has a majority of compensatory effects on its common pharmacological
targets. These pairs are not considered in our analysis (they belong to the incoherent tail of the
histogram in Fig. 3.30).
In DrugBank a set of "BioInteractions" (i.e., drug-drug interactions) is reported for each drug,
based on common targets, but also on other mechanisms like assimilation and clearance (using
information on enzymes and transporters affecting the drugs). These drug-drug interactions are
limited to pharmacological targets, and essentially overlap with the pharmacological drug pairs
used in our analysis and shown for instance in Fig. 3.31. Having lumped together many modes
of action into positive and negative signs, however, allows us to perform a further step, namely
to quantify the level of synergism of these drug-drug interactions and hence search for pairs with
high synergistic benefit. Furthermore, DrugBank biointeractions do not take into account off-
targets as we do here, hence no investigation of side effect is possible at all if we limit ourself to
the information currently provided by DrugBank.
Our definition of synergism and side effect can be limited or misleading in some cases. Other,
more sophisticated, definitions can obviously be adopted for this scope. Variants of the approach
discussed here for computing the synergism and side effect are for instance to replace the main
target / off-target distinction that we use with some other criteria, like an ontological classifica-
tion of the main targets of a drug (often known), or a co-localization on a specific pathway of
interest for a disease. Clearly dosage and timing of compound application are factors that could
be taken into account in a model. In some cases, the information on pharmacodynamics, assim-
ilation and clearance mechanisms available in DrugBank could be used for this scope, but it is
unlikely to be feasible at network level. A caveat in this case is that very little can be said on how
data on single drug response remain valid for mixing of drugs, unless extensive experimental
evaluation is performed.
Only a limited amount of the information available on DrugBank is used to construct the mode
of action of a drug on a target in this thesis. Including more available data from DrugBank and
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other databases would lead to a more complete result. For example, some modes of action, such
as partial agonist, can be classified as being positive or negative depending on certain conditions.
If we could add such conditions to the variables more refined result would be reached. When
looking to the side effect part, a possible variable that could be taken into account would be the
strength of interaction of a drug on the off-targets of a second drug, and not only considering if it
is positive or negative.
Regarding the lack of available data of the E.Coli and Yeast organisms, one thing that could be
done is extract information from other databases such as RegulonDB or EcoCyc. RegulonDB and
EcoCyc databases contain information about the Escherichia coli (strain K-12). Similar databases
exist also for Yeast.
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